Vividion has integrated multiple technologies into its platform that enable the company to discover and develop therapies for well-known but previously undruggable targets. The platform has the ability to find unknown or cryptic functional pockets on drug targets, interact with those pockets using its proteome-trained covalent chemistry library, and ensure precise selectivity across the entire proteome with industrial scale chemoproteomics capabilities.

Using this platform, Vividion is advancing a number of selective small-molecule therapies. The company will begin with antagonists for the treatment of the nuclear factor-erythroid 2 (NRF2) mutant and NRF2-addicted cancers, as well as agonists for the treatment of inflammatory diseases. Additionally, a collaboration with Bristol Myers Squibb will advance a program against a transcription factor target for the treatment of both oncology and immunology indications.

The financing was co-led by new investors Logos Capital and Boxer Capital.

Vividion, Roche partner for small-molecule drug discovery
Biotechnology company Vividion Therapeutics has signed an exclusive worldwide option and license agreement with Roche.